Sample sociodemographics, risk behaviours, sexual healthcare-seeking behaviours and sexualised drug use in the past year by perceived HIV status, 2013–2016
| Perceived current HIV status | ||||||
| HIV negative/unknown status | HIV positive | |||||
| 2013 (n=801) | 2016 (n=679) | 2013 (n=104) | 2016 (n=60) | |||
| % (n) | % (n) | P value | % (n) | % (n) | P value | |
| Age (years) | 0.001 | 0.161 | ||||
| 16–24 | 11.3 (88) | 11.0 (74) | 0.0 (0) | 3.4 (2) | ||
| 25–34 | 37.4 (291) | 46.4 (312) | 24.2 (24) | 30.5 (18) | ||
| 35–44 | 30.6 (238) | 28.5 (192) | 45.5 (45) | 33.9 (20) | ||
| ≥45 | 20.7 (161) | 14.1 (95) | 30.3 (30) | 32.2 (19) | ||
| Ethnicity | 0.368 | 0.914 | ||||
| White | 80.7 (644) | 78.8 (532) | 87.3 (89) | 86.7 (52) | ||
| Non-white | 19.3 (154) | 21.2 (143) | 12.8 (13) | 13.3 (8) | ||
| Sexual orientation | 0.029 | 0.285 | ||||
| Gay/homosexual | 93.7 (703) | 92.5 (608) | 97.9 (94) | 98.2 (56) | ||
| Bisexual | 5.7 (43) | 5.9 (39) | 2.1 (2) | 0.0 (0) | ||
| Straight/heterosexual | 0.4 (3) | 0.2 (1) | 0.0 (0) | 0.0 (0) | ||
| Other | 0.1 (1) | 1.4 (9) | 0.0 (0) | 1.7 (1) | ||
| Years of education after 16 | 0.986 | 0.054 | ||||
| 0–2 | 20.3 (161) | 20.3 (137) | 18.5 (19) | 31.7 (19) | ||
| 3 or more | 79.7 (632) | 79.7 (539) | 81.5 (84) | 68.3 (41) | ||
| Employed | 0.196 | 0.167 | ||||
| Yes | 88.0 (703) | 90.1 (610) | 85.3 (87) | 76.7 (46) | ||
| No | 12.0 (96) | 9.9 (67) | 14.7 (15) | 23.3 (14) | ||
| Number of male partners in the past year | 0.116 | 0.899 | ||||
| 0 | 3.62 (29) | 2.6 (17) | 7.7 (8) | 5.3 (3) | ||
| 1 | 21.6 (173) | 26.3 (170) | 15.4 (16) | 21.1 (12) | ||
| 2–4 | 21.6 (173) | 20.4 (132) | 10.6 (11) | 10.5 (6) | ||
| 5–10 | 23.0 (184) | 24.7 (160) | 15.4 (16) | 14.0 (8) | ||
| >10 | 30.2 (242) | 26.0 (168) | 51.0 (53) | 49.1 (28) | ||
| Number of casual CAI partners in the past year | <0.001 | 0.035 | ||||
| 0 | 76.2 (498) | 54.7 (321) | 55.1 (49) | 34.6 (18) | ||
| 1 | 15.1 (99) | 25.2 (148) | 12.4 (11) | 11.5 (6) | ||
| 2–4 | 5.7 (37) | 11.2 (66) | 4.5 (4) | 15.4 (8) | ||
| 5+ | 3.0 (20) | 8.9 (52) | 28.1 (25) | 38.5 (20) | ||
| Diagnosed with STI in the past year | 0.019 | 0.171 | ||||
| No | 86.6 (679) | 82.2 (557) | 68.9 (71) | 58.3 (35) | ||
| Yes | 13.4 (105) | 17.8 (121) | 31.1 (32) | 41.7 (25) | ||
| Specific STI diagnoses in the past year | ||||||
| Chlamydia | 5.1 (41) | 2.4 (16) | 0.006 | 12.5 (13) | 6.7 (4) | 0.238 |
| Gonorrhoea | 7.2 (58) | 12.1 (82) | 0.002 | 20.2 (21) | 31.7 (19) | 0.099 |
| Syphilis | 1.9 (15) | 2.1 (14) | 0.794 | 4.8 (5) | 21.7 (13) | 0.001 |
| Lymphogranuloma venereum | 0.6 (5) | 0.6 (4) | 1.000 | 0.0 (0) | 1.7 (1) | 0.366 |
| Hepatitis C | 0.1 (1) | 0.2 (1) | 1.000 | 0.0 (0) | 1.7 (1) | 0.366 |
| Other STI* | 0.8 (6) | 1.9 (13) | 0.047 | 1.9 (2) | 0.0 (0) | 0.533 |
| Attended a sexual health clinic in the past year | 0.002 | 0.178 | ||||
| No | 50.6 (400) | 42.5 (285) | 9.7 (10) | 16.9 (10) | ||
| Yes | 49.3 (390) | 57.5 (385) | 90.3 (93) | 83.1 (49) | ||
| Number of HIV tests in the past year | <0.001 | |||||
| 0 | 38.1 (294) | 27.4 (181) | ||||
| 1 | 29.4 (227) | 25.9 (171) | ||||
| 2+ | 32.4 (250) | 46.7 (309) | ||||
| Sexualised use of drugs in the past year | ||||||
| Ketamine | 9.4 (73) | 7.7 (52) | 0.247 | 26.7 (27) | 15.0 (9) | 0.084 |
| GHB/GBL | 8.9 (69) | 10.0 (68) | 0.445 | 24.8 (25) | 30.0 (18) | 0.467 |
| Mephedrone | 16.0 (125) | 13.8 (94) | 0.245 | 27.7 (28) | 31.7 (19) | 0.595 |
| Methamphetamine | 5.6 (44) | 5.3 (36) | 0.777 | 23.8 (24) | 28.3 (17) | 0.520 |
| Any chemsex† | 20.9 (163) | 18.7 (127) | 0.301 | 41.6 (42) | 41.7 (25) | 0.992 |
| Injected drug use | 2.9 (22) | 1.8 (12) | 0.187 | 12.1 (12) | 22.0 (13) | 0.099 |
Denominators may vary due to missing data.
*Other STI reported include genital warts (5), genital herpes (4), pubic lice (4), non-specific urethritis (NSU; 3), scabies (1) or unspecified other STI (4).
†Chemsex is defined as the use of any of the following drugs just before or during sex: ketamine, mephedrone, GHB/GBL or methamphetamine.
CAI, condomless anal intercourse; GBL, gamma-butyrolactone; GHB, gamma-hydroxybutyrate.